Clinical trials: Current Smoker
Non Small Cell Lung Cancer
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
The purpose of this study is to compare two different approaches to treating non-small cell lung cancer (NSCLC) in East Asian never-smoker participants.
- Trial name
- NCT01017874
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 12 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 236 people
- Sponsor
- Eli Lilly and Company
COPD (Chronic Obstructive Pulmonary Disease)
RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative
The study hypothesis is that symptomatic current and former smokers with spirometric values within the normal range (post-bronchodilator FEV1/FVC≥0.70 and post-BD FVC ≥ 70% predicted will still derive symptomatic benefit from…
- Trial name
- RETHINC (NCT02867761)
- Testing
- Indacaterol/Glycopyrrolate
- Where
- 16 sites in United States
- Volunteers
- 780 people
- Sponsor
- University of Michigan
Tobacco Use Cessation, Tobacco Use Disorder
Progesterone & Postpartum Relapse to Smoking
The primary goal of this project is to investigate the potential efficacy of exogenous progesterone (with supplemental relapse prevention counseling) on postpartum relapse in new mothers.
- Trial name
- NCT01798394
- Testing
- Progesterone
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Periodontitis, Periodontal Diseases
Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers
The purpose of this study is to determine in current and non-smokers the clinical and microbiological effects of 3 therapies: scaling and root planing (SRP) alone; SRP in combination with the orally administered antibiotic…
- Trial name
- NCT00066066
- Testing
- Scaling and root planing, Metronidazole, Amoxicillin
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- The Forsyth Institute
Bronchial Dysplasia, Tobacco Smoking
Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers
The goal of this clinical research study is to determine whether the PD-1 inhibitor (Programmed cell death protein 1) nivolumab improves premalignant bronchial dysplastic lesions in subjects that are at high risk for the…
- Conditions
- Bronchial Dysplasia, Tobacco Smoking, History of Non-Small Cell Lung Cancer, History of Head and Neck Cancer
- Trial name
- NCT03347838
- Testing
- Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- University of Colorado, Denver
Healthy Non-smoker
Matrix on Fruit Constituent Bioavailability
Primary objective is to evaluate the influence of matrix on the bioavailability of key phytochemical constituents in fruits and their subsequent effect on chronic disease risk factors.
- Trial name
- FRT (NCT01908634)
- Testing
- Milk-based Strawberry Beverage without meal, Water-Based Strawberry Beverage without meal, Milk-based strawberry Beverage with meal
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Non-Small-Cell Lung Cancer
A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer
The purpose of this study is to compare the combination of erlotinib and pemetrexed versus either pemetrexed alone and erlotinib alone, in terms of progression-free survival (time until the objective worsening of the disease) in…
- Trial name
- NCT00550173
- Testing
- pemetrexed, erlotinib
- Where
- 29 sites in Brazil, China and 5 more
- Volunteers
- 247 people
- Sponsor
- Eli Lilly and Company
Non-squamous Non-small Cell Lung Cancer
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small…
- Trial name
- NCT02264990
- Testing
- Paclitaxel, Carboplatin, Cisplatin
- Where
- 140 sites in United States, Argentina and 18 more
- Volunteers
- 595 people
- Sponsor
- AbbVie
Smoking
Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L
The purpose of this study is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD, i.e., subjective effects) profiles, and the safety and tolerability of the nicotine-containing aerosol delivered by Platform 3 Liquid…
- Trial name
- NCT02532374
- Testing
- Nicorette® inhalator, P3L
- Where
- New Zealand
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Tobacco Use Disorder
Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers
This randomized phase II trial studies the effects of aspirin and zileuton on genes related to tobacco use in current smokers. Aspirin and zileuton may interfere with genes related to tobacco use and may be useful in preventing…
- Trial name
- NCT02348203
- Testing
- Aspirin, Laboratory Biomarker Analysis, Zileuton
- Where
- 2 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Lung Carcinoma, Tobacco Use Disorder
Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers
This randomized phase II trial studies the safety and effects of acetylsalicylic acid (aspirin) taken continuously or intermittently on gene expression in the nasal tissue of current smokers.
- Trial name
- NCT02123849
- Testing
- Aspirin, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Tobacco Use Cessation
Project Q Pilot: Smoking Cessation for Light Smokers
The purpose of this pilot study is to evaluate the feasibility, acceptability, and preliminary efficacy of an intervention to promote smoking cessation among light smokers.
- Trial name
- NCT03416621
- Testing
- Cognitive behavioral cessation counseling, Counseling and active drug intervention
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Duke University
Non-small Cell Lung Cancer, Squamous Lung Dysplasia
Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
This randomized phase II trial is studying inositol to see how well it works compared with a placebo in preventing lung cancer in current or former smokers with bronchial dysplasia.
- Trial name
- NCT00783705
- Testing
- inositol
- Where
- 4 sites in United States, Canada
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute (NCI)
Nicotine Dependent Cigarette Smoker
The Get Quit - Stay Quit Study
Narrative: Tobacco smoking remains the single biggest cause of premature death in the United States and the leading cause of cancer and death from cancer.
- Trial name
- GQSQ (NCT01980485)
- Testing
- Lung Age feedback and exhaled carbon monoxide, No Lung Age Feedback
- Where
- 4 sites in United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Tobacco Use Disorder
A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers
The purpose of this study is to assess the bioequivalence of the 21mg nicotine transdermal patch from GSK Dungarvan (Test) compared to the 21mg nicotine transdermal patch currently manufactured by Alza (Reference).
- Trial name
- NCT05024747
- Testing
- NicoDerm CQ patch (GSK Dungarvan), NicoDerm CQ (Alza)
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- HALEON
Precancerous Condition, Stage I Non-small Cell Lung Cancer
Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
This randomized phase II trial is studying sulindac to see how well it works compared to a placebo in preventing lung cancer in current or former smokers with bronchial dysplasia.
- Conditions
- Precancerous Condition, Stage I Non-small Cell Lung Cancer, Tobacco Use Disorder
- Trial name
- NCT00368927
- Testing
- sulindac
- Where
- 6 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Smoking, Tobacco Use
IQOS (Non-Cigarette Tobacco Product) Pilot Study
A novel type of non-cigarette tobacco product was recently approved for sale in the US, the heated tobacco product (HTP) IQOS. IQOS may be less harmful than cigarettes, and there are some reports that it may produce more…
- Trial name
- NCT04357379
- Testing
- IQOS
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Chronic Obstructive Pulmonary Disease, COPD
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT02449018
- Testing
- QBW251
- Where
- 16 sites in United States, Poland
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Nicotine Dependence
Testing Financial Incentive Interventions in Dyadic-Smoker Couples
The proposed study investigates the feasibility and efficacy of FITs in dual-smoker couples [DSCs]. The core design is a three-group mixed repeated measures design, in which participants are randomized into one of three…
- Trial name
- NCT04832360
- Testing
- Financial Incentives
- Where
- United States
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- University of Georgia
Basic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor
Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine
The aim of this study is to test whether the attention-enhancing effects of low-dose nicotine can be enhanced by the drug galantamine, FDA-approved for the treatment of Alzheimer's disease.
- Trial name
- GalaNic (NCT02420327)
- Testing
- Nicotine patch and galantamine capsule
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore